CLINICAL RESEARCH

We are looking for patients to test a new oral medication for sufficient skin involvement (diffuse systemic sclerosis) in a one-year placebo-controlled trial. Patients should have disease less than or equal to five years duration and should have active skin disease. Low-dose prednisone can be continued but other medications will need to be stopped. If you are possibly interested, please call.

Stanique Thomas
310-297-6812. or email at:
Stanique.pa.clinicalresearch@gmail.com.

There is a new trial available, testing an oral cannabinoid affecting two mechanisms for fibrosis. The trial is a 12-week rising dose trial versus placebo. Patients must have sufficient skin involvement(diffuse disease) and may have disease for up to six years. Most background medications and low-dose prednisone will be allowed. If you are possibly interested, please call Omar Aly at. 310-297-6812. or email at: Omar.pa.clinicalresearch@gmail.com

We are looking for patients for a 24-week trial of an intravenous medication (given every three weeks) versus placebo. There will be an additional 24-week follow-up. Patients must have sufficient skin involvement (modified Rodman skin score of 10 or more and diffuse disease) anddisease duration of up to five years. Background mycophenolate (CellCept/Myofortic) and low-dose prednisone are allowed but not required. If you are possibly interested, please call Stanique Thomas at. 310-297-6812. or email at: Stanique.pa.clinicalresearch@gmail.com

1. Picori
2. Prometheus
3. Eustar
4. Spin
5. Bio Banking
6. Male Fertility
7. Kadmon